Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma

✍ Scribed by David M. Reese; Michelle Corry; Eric J. Small

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 77 KB
• Volume: 88
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(20000315)88:6<1310::aid-cncr6>3.0.co;2-6

✦ Synopsis

BACKGROUND.

The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional FUDR with biologic response modifiers (BRMs) has not been evaluated extensively in patients with metastatic RCC.

METHODS.

Thirty-nine previously untreated patients with metastatic RCC were treated with infusional FUDR at 0.075 mg/kg/day for 14 days of a 28-day cycle.

Beginning with the second cycle of FUDR, 24 patients received subcutaneous interferon-␣-2b (3 million U 3 times a week for Weeks 1 and 2) and 15 received subcutaneous interleukin-2 (IL-2) (5 million U/m 2 5 days a week for 3 weeks, followed by 1 week off). The dose of FUDR was increased by 0.025 mg/kg each cycle until the maximum tolerated dose for each patient was reached.